NEXTGENPCR: 30 cycli, 3 temperatures, less than 2 minutes

MBS Inks Deal with Canon BioMedical for NEXTGENPCR distribution in US and Canada

Partnership rapidly provides NEXTGENPCR to US and Canadian customers

Amsterdam, April 23rd 2018:

Dutch biotechnology company Molecular Biology Systems (MBS) today announced it will launch its revolutionary NEXTGENPCR thermal cycler in the US and Canada through Canon BioMedical, Inc., a wholly owned subsidiary of Canon U.S.A., Inc. focused on empowering the biomedical research and healthcare communities by developing, manufacturing, and marketing innovative technologies and solutions.

According to the latest surveys, the global life sciences instrumentation market continues to grow at a CAGR of 8.2% and is predicted to be worth $85.1 billion by 2022. The US and Canada account for the largest share, fueled by a rapid adoption rate of novel technologies, the large number of life science research studies conducted in the region, and increased funding for life science research activities.

Read the whole article:  MBS Inks Deal with Canon BioMedical

Comments are closed here.